X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6228) 6228
Publication (519) 519
Newsletter (170) 170
Book Review (31) 31
Conference Proceeding (12) 12
Book Chapter (11) 11
Book / eBook (5) 5
Dissertation (3) 3
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (3024) 3024
bleomycin (2694) 2694
humans (2688) 2688
bleomycin - pharmacology (2679) 2679
male (1974) 1974
mice (1665) 1665
index medicus (1515) 1515
female (1328) 1328
pharmacology & pharmacy (899) 899
oncology (889) 889
rats (865) 865
pulmonary fibrosis - chemically induced (839) 839
pulmonary fibrosis (800) 800
bleomycin - administration & dosage (759) 759
adult (736) 736
biochemistry & molecular biology (661) 661
middle aged (652) 652
lung - pathology (591) 591
cells, cultured (587) 587
bleomycin - toxicity (586) 586
fibrosis (576) 576
lung - drug effects (572) 572
respiratory system (568) 568
pulmonary fibrosis - pathology (544) 544
antineoplastic combined chemotherapy protocols - therapeutic use (527) 527
mice, inbred c57bl (522) 522
dna damage (511) 511
bleomycin - adverse effects (501) 501
antibiotics, antineoplastic - pharmacology (491) 491
cell line (485) 485
disease models, animal (474) 474
lung - metabolism (468) 468
cell biology (463) 463
pulmonary fibrosis - metabolism (456) 456
expression (455) 455
dose-response relationship, drug (452) 452
time factors (435) 435
cancer (432) 432
inflammation (413) 413
aged (397) 397
bleomycin - therapeutic use (395) 395
research (386) 386
cell survival - drug effects (381) 381
cells (370) 370
chemotherapy (357) 357
antineoplastic agents - pharmacology (351) 351
dna (331) 331
fibroblasts - drug effects (331) 331
apoptosis (328) 328
collagen (326) 326
cricetinae (321) 321
respiratory tract diseases (318) 318
analysis (312) 312
fibroblasts (312) 312
pulmonary fibrosis - drug therapy (310) 310
adolescent (307) 307
fibroblasts - metabolism (285) 285
toxicology (279) 279
dna repair (273) 273
lung diseases (259) 259
research article (256) 256
doxorubicin - administration & dosage (254) 254
disease (253) 253
kinetics (252) 252
medicine, research & experimental (244) 244
antineoplastic combined chemotherapy protocols - adverse effects (242) 242
cisplatin - administration & dosage (242) 242
lung fibrosis (238) 238
bleomycin - metabolism (232) 232
activation (231) 231
growth-factor-beta (229) 229
rats, sprague-dawley (227) 227
oxidative stress (226) 226
proteins (224) 224
dna - metabolism (223) 223
rodents (222) 222
cell line, tumor (219) 219
cisplatin (219) 219
pulmonary fibrosis - prevention & control (217) 217
vincristine - administration & dosage (216) 216
immunology (212) 212
gene expression (210) 210
combined modality therapy (207) 207
base sequence (206) 206
pathogenesis (206) 206
inhibition (205) 205
apoptosis - drug effects (204) 204
in vitro techniques (204) 204
collagen - metabolism (201) 201
drug synergism (201) 201
mutation (201) 201
lungs (199) 199
treatment outcome (199) 199
cell division - drug effects (198) 198
dna - drug effects (193) 193
cisplatin - pharmacology (189) 189
bleomycin - analogs & derivatives (187) 187
therapy (186) 186
hydroxyproline - metabolism (183) 183
lymphocytes - drug effects (182) 182
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5985) 5985
Japanese (179) 179
Chinese (129) 129
German (39) 39
Russian (39) 39
French (23) 23
Spanish (10) 10
Polish (8) 8
Italian (4) 4
Croatian (3) 3
Hungarian (2) 2
Hebrew (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 12/2014, Volume 9, Issue 12, p. e114766
In the present study, we noted that bleomycin induced growth inhibitory action was augmented by all the polyunsaturated fatty acids (PUFAs) tested on human... 
CARCINOMA-CELLS | CANCER-CELLS | NUDE-MICE | INDUCED DIABETES-MELLITUS | LIPID-PEROXIDATION | MULTIDISCIPLINARY SCIENCES | TUMOR-CELLS | GAMMA-LINOLENIC ACID | ARACHIDONIC-ACID | EICOSAPENTAENOIC ACID | PROSTAGLANDIN E-2 | Prostaglandins - pharmacology | Humans | Leukotrienes - pharmacology | Fatty Acids, Unsaturated - pharmacology | Lipoxins - pharmacology | Antioxidants - pharmacology | Fatty Acids, Unsaturated - metabolism | Cyclooxygenase Inhibitors - pharmacology | CD59 Antigens - pharmacology | Docosahexaenoic Acids - pharmacology | Time Factors | Arachidonic Acid - pharmacology | Lipid Peroxidation - drug effects | Cell Line, Tumor | Cell Extracts | Cell Proliferation - drug effects | Cell Death - drug effects | Nitric Oxide - metabolism | Lipoxygenase Inhibitors - pharmacology | Neuroblastoma - pathology | Bleomycin - toxicity | Unsaturated fatty acids | Prostaglandins | Bleomycin | Metabolites | Lectins | Neuroblastoma | Omega-3 fatty acids | Polyunsaturated fatty acids | Oxidizing agents | Science | Lipid peroxidation | Prostaglandin E2 | Cytotoxicity | Lipids | Superoxide dismutase | Metastasis | Kinases | Docosahexaenoic acid | Neuroblastoma cells | Antioxidants | Cell growth | Oxidants | Rodents | Cell cycle | Peroxides | Peroxidase | Inhibition | Pretreatment | Drug dosages | Glutathione | Glutathione peroxidase | Engineering schools | Lipoxin A4 | Nordihydroguaiaretic acid | Superoxide | Breast cancer | Fatty acids | Studies | Leukotrienes | Indomethacin
Journal Article
Oncogene, ISSN 0950-9232, 10/2011, Volume 30, Issue 41, pp. 4261 - 4274
In the presence of sustained DNA damage occurring in S-phase or G2, normal cells arrest before mitosis and eventually become senescent. The checkpoint kinases... 
cyclin B1 | ATM | Chk2 | G2-M checkpoint | cell cycle | GENOTOXIC STRESS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MITOTIC CATASTROPHE | TRANSCRIPTIONAL REPRESSION | G CHECKPOINT | CELL BIOLOGY | GENOMIC INSTABILITY | RETINOBLASTOMA PROTEIN | ONCOLOGY | GENETICS & HEREDITY | P53-DEFICIENT CELLS | CELL-CYCLE EXIT | IONIZING-RADIATION | ATAXIA-TELANGIECTASIA | Protein Kinases - metabolism | G2 Phase Cell Cycle Checkpoints - physiology | Phosphorylation | Protein Kinases - genetics | Tumor Suppressor Proteins - antagonists & inhibitors | Humans | Immunoblotting | Male | Cyclin B1 - metabolism | Pyrones - pharmacology | Tumor Suppressor Protein p53 - genetics | Cell Cycle Proteins - antagonists & inhibitors | DNA-Binding Proteins - metabolism | Cyclin-Dependent Kinase Inhibitor p21 - genetics | G2 Phase Cell Cycle Checkpoints - drug effects | RNA Interference | Tumor Suppressor Proteins - genetics | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cell Cycle Proteins - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Antineoplastic Agents - pharmacology | Protein-Serine-Threonine Kinases - metabolism | Tumor Suppressor Proteins - metabolism | DNA-Binding Proteins - antagonists & inhibitors | HCT116 Cells | Cell Cycle Proteins - metabolism | Cells, Cultured | Protein-Serine-Threonine Kinases - genetics | Tumor Suppressor Protein p53 - metabolism | Cyclin B1 - genetics | Morpholines - pharmacology | Signal Transduction - genetics | Ataxia Telangiectasia Mutated Proteins | DNA-Binding Proteins - genetics | Piperazines - pharmacology | G2 Phase Cell Cycle Checkpoints - genetics | Signal Transduction - drug effects | Cell Line, Tumor | Checkpoint Kinase 2 | Bleomycin - pharmacology | Checkpoint Kinase 1 | Signal Transduction - physiology | DNA Damage | HeLa Cells | Cell division | Oxidative stress | Signal transduction | DNA damage | Cyclin-dependent kinases | Cell cycle | CHK2 protein | Epithelial cells | Mitosis | CHK1 protein | G2 phase | Genotoxicity | Osteosarcoma cells | p53 protein | Cyclin-dependent kinase | Chemotherapy | Fibroblasts | Cancer
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 04/1997, Volume 89, Issue 8, pp. 2959 - 2965
It is vital to develop effective therapy for children with acute lymphoblastic leukemia (ALL), in whom no remission occurs or who suffer relapse with current... 
INVITRO CHEMOSENSITIVITY | CELLS | IN-VITRO | GROWTH | CLINICAL PROGNOSIS | RESISTANCE PROFILES | HEMATOLOGY | EXPRESSION | MTT ASSAY | IMMUNOPHENOTYPE | CHILDREN | Recurrence | Vincristine - pharmacology | Cyclophosphamide - administration & dosage | Prednisolone - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Neoplastic Stem Cells - drug effects | Humans | Aclarubicin - administration & dosage | Child, Preschool | Drug Resistance, Neoplasm | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Asparaginase - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Dexamethasone - pharmacology | Neoplastic Stem Cells - pathology | Vincristine - administration & dosage | Melphalan - pharmacology | Child | Daunorubicin - administration & dosage | Infant, Newborn | Dexamethasone - administration & dosage | Tumor Cells, Cultured - drug effects | Etoposide - pharmacology | Etoposide - administration & dosage | Bleomycin - administration & dosage | Prednisolone - pharmacology | Remission Induction | Cytarabine - administration & dosage | Mitomycin - pharmacology | Cyclophosphamide - pharmacology | Adolescent | Bleomycin - pharmacology | Methotrexate - administration & dosage | Mitoxantrone - pharmacology | Mitomycin - administration & dosage | Methotrexate - pharmacology | Cyclophosphamide - analogs & derivatives | Cytarabine - pharmacology | Prognosis | Daunorubicin - pharmacology | Infant | Life Tables | Dose-Response Relationship, Drug | Doxorubicin - analogs & derivatives | Antineoplastic Agents - pharmacology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Doxorubicin - administration & dosage | Cell Survival | Asparaginase - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Bone Marrow - pathology | Aclarubicin - pharmacology | Doxorubicin - pharmacology | Drug Screening Assays, Antitumor
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2018, Volume 81, Issue 3, pp. 455 - 460
The purpose of this report is to describe, for the first time, the pharmacokinetics of dacarbazine (DTIC) and its metabolites... 
Pregnancy | Dacarbazine | Medicine & Public Health | Metabolites | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacokinetics | TRIMESTER | CANCER | METABOLITE 5-AMINOIMIDAZOLE-4-CARBOXAMIDE | WOMEN | PLASMA | 24-HOUR CREATININE CLEARANCE | ONCOLOGY | POSTPARTUM | CYP1A2 | NON-HODGKINS-LYMPHOMA | PHARMACOLOGY & PHARMACY | Dacarbazine - adverse effects | Area Under Curve | Hodgkin Disease - pathology | Humans | Antineoplastic Agents, Alkylating - administration & dosage | Drug Monitoring - methods | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Antineoplastic Agents, Alkylating - blood | Hodgkin Disease - drug therapy | Pregnancy Complications, Neoplastic - drug therapy | Adult | Dacarbazine - pharmacokinetics | Female | Infant, Newborn | Dacarbazine - administration & dosage | Treatment Outcome | Antineoplastic Agents, Alkylating - pharmacokinetics | Pregnancy Complications, Neoplastic - pathology | Administration, Intravenous | Dacarbazine - blood | Bleomycin - pharmacology | Vinblastine - pharmacology | Antineoplastic Agents, Alkylating - adverse effects | Neoplasm Staging | Doxorubicin - pharmacology | Pregnancy Outcome | Anthracyclines | Lymphomas | Pregnant women | Vinblastine | Cytochrome P450 | Case reports | Pharmacology | Liquid chromatography | Gestation | CYP1A2 protein | Metabolism | High-performance liquid chromatography | Doxorubicin | Lymphoma | Postpartum | Bleomycin | Imidazole | Drug metabolism | Remission
Journal Article
American Journal of Physiology - Lung Cellular and Molecular Physiology, ISSN 1040-0605, 07/2013, Volume 305, Issue 1, pp. L33 - L41
Earlier work showed that apoptosis of alveolar epithelial cells (AECs) in response to endogenous or xenobiotic factors is regulated by autocrine generation of... 
Substituted peptide receptor antagonists | BRICHOS domain mutations | ADAM17/ TACE | Idiopathic pulmonary fibrosis | LUNG FIBROSIS | DE-NOVO | ACTIVATION | PHYSIOLOGY | SURFACTANT PROTEIN-C | II GENERATION | idiopathic pulmonary fibrosis | ENDOPLASMIC-RETICULUM STRESS | INDUCTION | substituted peptide receptor antagonists | BLEOMYCIN-INDUCED APOPTOSIS | CASPASE INHIBITOR | RESPIRATORY SYSTEM | IDIOPATHIC PULMONARY-FIBROSIS | ADAM17/TACE | Vasoconstrictor Agents - pharmacology | Autocrine Communication | Angiotensin II - pharmacology | Antihypertensive Agents - pharmacology | Pulmonary Alveoli - pathology | Endoplasmic Reticulum Stress - drug effects | Apoptosis - drug effects | Epithelial Cells - drug effects | Humans | Angiotensin Receptor Antagonists - pharmacology | Cells, Cultured | Pulmonary Surfactant-Associated Protein C - metabolism | Epithelial Cells - pathology | Peptide Fragments - pharmacology | Leupeptins - pharmacology | Signal Transduction - drug effects | Pulmonary Alveoli - drug effects | Pulmonary Surfactant-Associated Protein C - genetics | Receptors, Angiotensin - chemistry | Angiotensin I - pharmacology | Antineoplastic Agents - pharmacology | Pulmonary Surfactant-Associated Protein C - antagonists & inhibitors | Physiological aspects | Stress (Physiology) | Epithelial cells | Endoplasmic reticulum | Health aspects | Angiotensin | Proteins | Lung diseases | Mutation | Surfactants | ACE inhibitors | Cells | Apoptosis | Call for Papers | TACE | ADAM17
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 07/2001, Volume 133, Issue 5, pp. 687 - 694
Fibrosis leads to chronic impairment of cardiac and renal function and thus reversal of existing fibrosis may improve function and survival. This project has... 
fibrosis | Diabetes | pirfenidone | spironolactone | Spironolactone | Pirfenidone | Fibrosis | MYOCARDIUM | LUNG FIBROSIS | ACTIVATION | BLEOMYCIN HAMSTER MODEL | TRANSCRIPTIONAL LEVEL | HEART | RESPONSES | INHIBITION | GENE-EXPRESSION | HYPERTENSIVE RATS | PHARMACOLOGY & PHARMACY | diabetes | Norepinephrine - pharmacology | Kidney - pathology | Rats, Wistar | Body Weight - drug effects | Myocardial Contraction - drug effects | Male | Quinolines - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Kidney - metabolism | Spironolactone - pharmacology | Mineralocorticoid Receptor Antagonists - pharmacology | Aorta, Thoracic - drug effects | Diabetes Mellitus, Experimental - metabolism | Fibrosis - prevention & control | Diabetes Mellitus, Experimental - physiopathology | Vasoconstrictor Agents - pharmacology | Kidney - drug effects | Rats | Myocardium - pathology | Aorta, Thoracic - physiopathology | Vasoconstriction - drug effects | Blood Glucose - drug effects | Calcium Chloride - pharmacology | Eating - drug effects | Animals | Heart Ventricles - physiopathology | Drinking - drug effects | Heart Ventricles - metabolism | Blood Glucose - metabolism | In Vitro Techniques | Thiadiazines - pharmacology | Pyridones - pharmacology | Heart Ventricles - drug effects | Papers
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 08/2017, Volume 76, Issue 8, pp. 1467 - 1475
ObjectivesJanus kinase 2 (JAK2) has recently been described as a novel downstream mediator of the pro-fibrotic effects of transforming growth factor-β.... 
GROWTH-FACTOR-BETA | SCLERODERMA | INDUCED PULMONARY-FIBROSIS | FIBROTIC RESPONSE | KINASE | EXPERIMENTAL DERMAL FIBROSIS | MYELOPROLIFERATIVE NEOPLASMS | MICE | RHEUMATOLOGY | SYSTEMIC-SCLEROSIS | INDUCED FIBROBLAST ACTIVATION | Immunohistochemistry | Antibiotics, Antineoplastic - toxicity | Humans | Middle Aged | Male | Janus Kinase 1 - metabolism | Janus Kinase 2 - metabolism | Adult | Pulmonary Fibrosis - metabolism | Phosphorylation - drug effects | Real-Time Polymerase Chain Reaction | Janus Kinase 2 - antagonists & inhibitors | Bleomycin - toxicity | Disease Models, Animal | Fibroblasts - metabolism | Pyrazoles - pharmacology | Lung - pathology | Pyrimidines - pharmacology | Janus Kinase 1 - antagonists & inhibitors | Lactams, Macrocyclic - pharmacology | Sulfonamides - pharmacology | Janus Kinase 1 - drug effects | Blotting, Western | Benzoquinones - pharmacology | Transforming Growth Factor beta - pharmacology | Animals | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Fibroblasts - drug effects | Lung - drug effects | Fibrosis | Scleroderma, Systemic | Janus Kinase 2 - drug effects | Pulmonary Fibrosis - chemically induced | Mice | Protein Kinase Inhibitors - pharmacology | Biotechnology | Hsp90 protein | Research funding | Transforming growth factor | Lung diseases | Gene expression | Kinases | Myelodysplastic syndrome | Proteins | Signal transduction | Bleomycin | Pulmonary fibrosis | Janus kinase 2 | Fibroblasts | Janus kinase | Skin | Mutation | Growth factors | Polyclonal antibodies | Tumors
Journal Article
Chemical Research in Toxicology, ISSN 0893-228X, 02/2017, Volume 30, Issue 2, pp. 715 - 725
A major concept to sensitize cancer cells to DNA damaging agents is by inhibiting proteins in the DNA repair pathways. X-family DNA polymerases play critical... 
Antibiotics, Antineoplastic - pharmacology | Biphenyl Compounds - pharmacology | Humans | Enzyme Inhibitors - pharmacology | Cell Line, Tumor | Bleomycin - pharmacology | Kinetics | DNA Polymerase beta - antagonists & inhibitors | Lignans - pharmacology | Index Medicus
Journal Article